Applications and Implications Revision Notes | A Level AQA Biology

1. Why Recombinant DNA Technology Changes Everything

Here is the central puzzle: how can a human gene, taken from a human cell, be inserted into a bacterium and then produce a human protein? The answer lies in one of the most elegant facts in all of biology — the genetic code is universal.

Every living organism on Earth uses the same codons to specify the same amino acids, and the same core machinery of transcription and translation to read DNA and build proteins. This means a gene transferred from one species to another can be read, transcribed, and translated by the recipient organism's ribosomes just as effectively as if it had always been there.

Recombinant DNA technology exploits this universality. A fragment of DNA is cut from a donor organism, joined to a vector (commonly a plasmid or virus), and introduced into a recipient cell. The recipient — now called a transgenic organism — carries and expresses the foreign gene. This is the foundation of everything that follows in this lesson: GM crops, insulin production, and gene therapy all rest on this single principle.

With the principle established, a practical question immediately arises: after you have attempted to insert a gene into millions of cells, how do you know which ones actually took it up? This is where marker genes become indispensable.

2. Marker Genes — Identifying Successful Transformation

Picture a scientist who has mixed recombinant plasmids with bacterial cells. Most bacteria will not take up the plasmid at all. Of those that do, some may have incorporated the plasmid without the gene of interest. The challenge is identifying the rare, successfully transformed cells from the vast majority that are unmodified.

A marker gene is inserted into the vector alongside the gene of interest. When the vector is successfully taken up, the marker gene is expressed too, giving the transformed cell a detectable characteristic. This allows scientists to screen large populations of cells and select only those that carry the recombinant DNA.

• Antibiotic resistance genes: transformed cells survive on antibiotic-containing growth media; non-transformed cells die.
• Fluorescent reporter genes (e.g. green fluorescent protein, GFP): transformed cells glow under ultraviolet light, making them visually identifiable.
• Enzyme-based colour markers: transformed cells produce an enzyme that converts a colourless substrate into a coloured product, changing colony colour.

You do not need to recall the names of specific marker genes for the written paper — the AQA specification is explicit on this. What you do need to understand is the principle: the marker gene provides a selectable or screenable phenotype that distinguishes transformed cells from non-transformed ones.

Marker genes are therefore the quality-control step in recombinant DNA technology. Once successfully transformed cells are identified, they can be cultured at scale to produce the desired protein or to generate a transgenic organism. This brings us to the wide range of applications — and the significant controversies — that surround this technology.

3. Applications of Recombinant DNA Technology

Recombinant DNA technology is applied across three major domains: agriculture, industry, and medicine. Each domain offers genuine benefits, but each also carries specific concerns that you will need to evaluate in exam questions.

3a. Agriculture

Genetically modified (GM) crops have been engineered to express genes from other organisms. A well-known example is Bt maize, which carries a gene from the bacterium Bacillus thuringiensis encoding a protein toxic to certain insect larvae. The maize plant expresses this protein, reducing crop losses without the need for chemical insecticides. Other GM crops have been engineered for herbicide tolerance, drought resistance, or enhanced nutritional profiles.

The humanitarian case for GM crops is substantial: higher yields can improve food security in regions affected by drought or pest pressure, and crops with enhanced nutritional content (such as Golden Rice, engineered to produce beta-carotene) could address specific nutrient deficiencies in populations where dietary variety is limited.

3b. Industry

Microorganisms transformed with recombinant DNA are used as biological factories. Bacteria or yeast carrying the human insulin gene produce human insulin protein, which is then extracted, purified, and used to treat diabetes. Before recombinant DNA technology, insulin was extracted from pig or cow pancreases — a process that was costly, limited in scale, and occasionally caused immune reactions in patients.

The same principle applies to the production of other therapeutic proteins: clotting factors for haemophilia, erythropoietin for anaemia, and human growth hormone. Recombinant enzymes are also used in industrial processes such as food production and biofuel manufacture.

3c. Medicine and Gene Therapy

Gene therapy is the direct application of recombinant DNA technology to treat disease in a patient. A functional copy of a gene is introduced into the patient's cells to compensate for a faulty or absent gene. The vector used to deliver the gene is often a modified virus — chosen because viruses are naturally efficient at entering cells and inserting genetic material.

There are two broad categories of gene therapy. Somatic gene therapy targets non-reproductive body cells; any changes affect only the treated individual and are not heritable. Germ-line gene therapy targets egg or sperm cells (or early embryos), meaning changes would be passed to future generations. Germ-line gene therapy is currently not permitted in humans in the UK due to profound ethical concerns.

Somatic gene therapy has shown clinical success in conditions such as severe combined immunodeficiency (SCID), where patients lack a functional immune system. Correcting the faulty gene in bone marrow stem cells can restore immune function. However, challenges remain: ensuring the gene inserts into a safe location in the genome, achieving long-lasting expression, and avoiding immune responses to the viral vector.

Gene therapy illustrates how recombinant DNA technology moves from the laboratory bench directly into clinical medicine. The same core steps — isolating a gene, inserting it into a vector, and introducing it into target cells — underpin both industrial protein production and therapeutic intervention. The difference lies in the target cell type and the intended outcome.

4. Interpreting Recombinant DNA Technology Data

AQA exam questions frequently present data — yield figures, clinical trial outcomes, or economic statistics — and ask you to interpret them in the context of recombinant DNA technology. The key skill is linking the data back to the underlying biological mechanism, not describing the numbers.

Worked example: Interpreting a Recombinant DNA Technology Data Set

A study compared insulin produced by recombinant bacteria with insulin extracted from pig pancreases. The recombinant insulin caused adverse immune reactions in 0.3% of patients; pig-derived insulin caused reactions in 4.7% of patients. Interpret this data in the context of recombinant DNA technology. [3 marks]

1. Recombinant insulin: 0.3% adverse reactions. Pig-derived insulin: 4.7% adverse reactions. Recombinant insulin causes approximately 15 times fewer adverse immune reactions. — Always quantify the difference — examiners award marks for precise comparative statements, not vague ones like 'less'.
2. Recombinant insulin is encoded by the human insulin gene expressed in bacteria. Its amino acid sequence is identical to human insulin. — Because the genetic code is universal, the bacterial ribosomes translate the human gene accurately, producing a protein with the correct human sequence. [M1]
3. The human immune system recognises human insulin as 'self' and does not mount an immune response against it. Pig insulin differs slightly in amino acid sequence and is recognised as 'non-self', triggering an immune reaction in some patients. — This is the mechanistic explanation the examiner is looking for — sequence identity leads to immunological tolerance. [M1]
4. The data support the use of recombinant DNA technology to produce human insulin, as it is safer for patients due to its identical amino acid sequence to endogenous human insulin. — A conclusion that directly references both the data and the technology earns the final mark. [A1]

Answer: Recombinant insulin causes far fewer adverse immune reactions (0.3% vs 4.7%) because it has an identical amino acid sequence to human insulin — the human gene is accurately translated by bacterial ribosomes due to the universality of the genetic code — so the immune system does not recognise it as foreign.

5. Evaluating Ethical, Financial, and Social Issues

Recombinant DNA technology sits at the intersection of science, economics, and politics. AQA expects you to evaluate — not merely list — the arguments on multiple sides, and to reach a reasoned conclusion. The command word 'evaluate' requires you to weigh evidence and make a judgement.

The ethical, financial, and social debates cluster around three main tensions: ownership and access, environmental risk, and the boundary between treatment and enhancement.

Environmentalists raise concerns about the uncontrolled spread of transgenes into wild populations — a process called gene flow. If a herbicide-resistance gene transferred from a GM crop to a wild relative, it could create 'superweeds' that are difficult to control. Anti-globalisation activists argue that large multinational corporations use patents on GM seeds to create economic dependency among farmers in developing nations, undermining local agricultural autonomy.

The humanitarian counter-argument is compelling: millions of people suffer from preventable conditions that recombinant DNA technology could address. Golden Rice, engineered to produce beta-carotene, could reduce vitamin A deficiency in populations where rice is a dietary staple. Recombinant insulin has transformed diabetes management globally. Dismissing these technologies entirely carries its own humanitarian cost.

Financial issues are equally significant. The cost of developing and trialling a new GM crop or therapeutic protein runs into hundreds of millions of pounds. Patent protection allows companies to recoup these costs, but it also means that the technology may be priced out of reach for the populations who need it most. This tension between innovation incentive and equitable access is central to the social debate.

When you encounter an 'evaluate' question on this topic, structure your response as: humanitarian benefit with evidence, environmental or social concern with evidence, a counter-argument, and a final reasoned judgement. Avoid listing points — the examiner is looking for weighing and conclusion.

6. Balancing Humanitarian Benefits Against Opposition

The debate around recombinant DNA technology is not 'science versus emotion'. Both sides draw on evidence, values, and legitimate concerns. Your task in an exam is to represent both positions fairly before reaching a conclusion — this is what distinguishes an A-grade evaluation from a one-sided account.

Consider the case of Golden Rice. Proponents argue it could prevent hundreds of thousands of cases of childhood blindness caused by vitamin A deficiency each year. Opponents argue that distributing diverse, locally grown vegetables would address the same deficiency without introducing GM organisms into ecosystems, and that Golden Rice represents a technological solution imposed on communities without adequate consultation.

Neither position is straightforwardly wrong. The humanitarian need is real; so are the concerns about ecological risk and corporate control. A balanced evaluation acknowledges both, weighs the strength of the evidence on each side, and arrives at a conclusion that is justified by that weighing — not by personal preference.

7. Exam Technique — Getting Full Marks on Applications Questions

Questions on recombinant DNA technology applications tend to use the command words 'evaluate', 'discuss', 'explain', and 'interpret'. Each demands a different response structure, and confusing them is one of the most common ways students lose marks.

For 'interpret' questions involving data, always: (1) identify the quantitative trend, (2) link it to the biological mechanism using precise terminology, and (3) state a conclusion that directly answers the question. Vague statements such as 'the results show it works better' will not earn marks — you need to explain why, using the science.

For 'evaluate' questions on ethical or social issues, the mark scheme typically rewards: a point in favour with supporting reasoning, a point against with supporting reasoning, and a conclusion. Six-mark questions expect you to develop at least two points on each side before concluding. Avoid bullet-point lists in extended-response answers — write in continuous prose to demonstrate the quality of your reasoning.

Every application of recombinant DNA technology — from GM crops to insulin production to gene therapy — rests on the same biological foundation: the universality of the genetic code allows transferred DNA to be expressed in any recipient organism. Understanding this principle, and being able to evaluate its applications critically, is the core skill this topic demands.